Journals / Abant Tıp Dergisi / 2016 / Cilt: 5 - Sayı: 2

Psychosomatıc dısorders relatıonshıp between metabolıc syndrome and panıc dısorder

Metabolik sendrom ile panik bozukluk arasındaki ilişki

Pages
91–100
Publication Date
2016-05-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The frequency of MS in patients with PD was significantly higher than in the healthy control group 46% vs 13%, p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTİVE: Metabolic syndrome MS is characterized by central obesity, hyperglycemia, dyslipidemia and hypertension.
📊
Key Findings & Data:METHODS: Fifty-nine age and sex-matched patients with PD 31 female and 28 male and healthy subjects 35 female and 24 male were included in this study.
💡
Conclusion & Impact:The frequency of MS in patients with PD was significantly higher than in the healthy control group 46% vs 13%, p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:panik bozukluk · metabolik sendrom · abdominal obesite

Abstract

OBJECTİVE: Metabolic syndrome MS is characterized by central obesity, hyperglycemia, dyslipidemia and hypertension. In recent years, many studies have investigated the prevalence of MS among psychiatric patients. İn this study, we aimed to investigate the frequency of MS in patients with Panic Disorder PD . METHODS: Fifty-nine age and sex-matched patients with PD 31 female and 28 male and healthy subjects 35 female and 24 male were included in this study. Panic disorder was diagnosed using DSM-IV criteria. MS was diagnosed according to the NCEP ATP National Cholesterol. Education Program Adult Treatment Panel 1 Abdominal obesity 2 A high triglyceride TG level 3 A low HDL High-density lipoprotein cholesterol level 4 A high blood pressure BP 5 A high fasting blood glucose FBG . RESULTS: The mean age of PD patients group was 42.2±12.1 and the mean age of control group was 40.7±12.7 p=0.491 . The frequency of MS in patients with PD was significantly higher than in the healthy control group 46% vs 13%, p

Özet

AMAÇ: Metabolik sendrom MS santral obezite, hiperglisemi, dislipidemi ve hipertansiyon ile karakterizedir. Son yıllarda birçok çalışmada psikiyatri hastaları arasında MS sıklığı araştırılmıştır. Bu çalışmada, Panik bozukluğu PB olan hastalarda MS sıklığını araştırmayı amaçladık. YÖNTEM: Panik Bozukluğu olan yaş ve cinsiyet uyumlu hasta 59 hasta 31 kadın ve 28 erkek ve 59 sağlıklı kontrol grubu 35 kadın ve 24 erkek çalışmaya alındı. DSM-IV kriterleri kullanılarak PB tanısı kondu. Metabolik sendrom tanısı NCEP ATP III Ulusal Kolesterol. Eğitim Programı Erişkin Tedavi Paneli önerileri doğrultusunda 1 Abdominal obezite 2 yüksek trigliserid TG düzeyi 3 Düşük HDL yüksek yoğunluklu lipoprotein kolesterol düzeyi 4 yüksek kan basıncı KB 5 yüksek açlık kan şekeri AKŞ seviyesine göre konuldu. BuLgular: Panik Bozukluk hasta grubunun yaş ortalaması 42.2 ± 12.1 ve kontrol grubunun yaş ortalaması 40.7 ± 12.7 p = 0.491 idi. Panik bozukluğu olan hastalarda MS sıklığı sağlıklı kontrol grubuna göre anlamlı olarak daha yüksek idi % 46 ve 13% , p

🔖

Cite This Article

KAYA, Y., DEMİR, E. Y., KESKİN, H., KAYA, A., BEKTAŞ, O. (2016). Psychosomatıc dısorders relatıonshıp between metabolıc syndrome and panıc dısorder. Abant Tıp Dergisi, Cilt: 5 - Sayı: 2, 91–100. https://ajindex.com/articles/448978

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Bloomgarden ZT. American Association of Clinical Endocrinologists (AACE) consensus conference on the insulin resistance syndrome: 25-26 August 2002, Washington, DC. Diabetes Care 2003;26:1297-303
  2. Hori Y, Nakatani K, Morioka K, Katsuki A, Gabazza EC, Yano Y, Nobori T, Adachi Y, Sumida Y. Insulin enhanced thrombin-activable fibrinolysis inhibitor expression through PI3 kinase/Akt pathway. Int J Mol Med 2005;15:265-8
  3. Calles-Escandon J, Mirza SA, Sobel BE, Schneider DJ. Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects. Diabetes 1998;47:290-3
  4. Lakka HM, Laaksonen DE, Lakka TA. The metabolic syndrome and total cardiovascular disease mortality in middleaged men. JAMA 2002; 288:27092716 5. Singh RB, Gupta S, Dherange P, De Meester F, Wilczynska A, Alam SE, Pella D, Wilson DW: Metabolic syndrome: a brain disease. Can J Physiol Pharmacol 2012, 90:1171–1183
  5. Chang HH, Chou CH, Chen PS, Gean PW, Huang HC, Lin CY, Yang YK, Lu RB: High prevalence of metabolic disturbances in patients with bipolar disorder in Taiwan. J Affect Disord 2009, 117:124–129 7. Kim B, Kim SJ, Son JI, Joo YH: Weight change in the acute treatment of bipolar I disorder: a naturalistic observational study of psychiatric inpatients. J Affect Disord 2008, 105:45– 52
  6. McElroy SL, Keck PE: Metabolic syndrome in bipolar disorder: a review with a focus on bipolar depression. J Clin Psychiatry 2014, 75:46–61 9. Van Winkel R, van Os J, Celic I: Psychiatric diagnosis as an independent risk factor for metabolic disturbances: results from a comprehensive, naturalistic screening program. J Clin Psychiatry 2008, 69:1319–1327
  7. Taylor V, MacQueen G: Associations between bipolar disorder and metabolic syndrome: a review. J Clin Psychiatry 2006, 67:1034–1041 11. McIntyre RS, Rasgon NL, Kemp DE, Nguyen HT, Law CW, Taylor VH, Woldeyohannes HO, Alsuwaidan MT, Soczynska JK, Kim B, Lourenco MT, Kahn LS, Goldstein BI: Metabolic syndrome and major depressive disorder: co-occurrence and pathophysiologic overlap. Curr Diab Rep 2009, 9:51–59 12. Goldbacher EM, Bromberger J, Matthews KA: Lifetime history of major depression predicts the development of the metabolic syndrome in middle-aged women. Psychosom Med 2009, 71:266– 272
  8. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on the Detection, Diagnosis, and Treatment of High Cholester